Kvíz spojený s průvodcem · Střední úroveň

WHO Guidance on AI in Health Quiz

Tests WHO ethical principles, autonomy, accountability, equity, lifecycle governance, and distinction from product certification.

Související vodicí cestyWho Guidance On AI In Health
Otázka 1 z 8

Co poskytuje doporučení WHO týkající se umělé inteligence ve zdraví?

Náhled každé otázky8 otázky

Odpovědi a vysvětlení se zobrazují, jak budete v kvízu.

  1. Co poskytuje doporučení WHO týkající se umělé inteligence ve zdraví?
    • A risk-based checklist that substitutes for national health law
    • Ethical and governance principles for responsible AI use
    • A binding regulation adopted by every WHO member state
    • A product-certification scheme for vendors
  2. What does protecting human autonomy mean in WHO’s framework?
    • Autonomy applies to data consent but not decisions about care
    • A clinician’s approval alone satisfies autonomy even without patient involvement
    • People remain in control of health systems and medical decisions
    • Patients must override any clinical recommendation in every circumstance
  3. Why establish a redress mechanism?
    • People need a way to question and seek a response to harmful algorithmic decisions
    • A complaint form with no review or response pathway
    • An updated score without explanation or remedy
    • An operator may close complaints without examining them
  4. How should inclusion and equity affect AI governance?
    • Assess who benefits, who may be excluded, and access across groups
    • Use the same aggregate score for every group without examining access
    • Prioritize availability to well-resourced hospitals because they produce more data
    • Treat equal model outputs as proof that access is equitable
  5. Jsou pokyny WHO certifikací produktu?
    • Yes; WHO guidance replaces local approval whenever a tool is used clinically
    • No; it is a governance framework and does not replace local regulation
    • Yes; publication by WHO certifies a vendor’s product
    • No; WHO guidance applies only to medical-device manufacturers
  6. When should an organization revisit governance controls?
    • Only before initial deployment because later review invalidates evaluation
    • When data or a model changes, but not when clinical workflow changes
    • Only after a regulator orders review
    • When models, data, or workflows change
  7. Které zveřejnění nejpříměji vysvětluje zamýšlené použití, důkazy a omezení nástroje AI pro zdraví?
    • Accessible documentation of intended use, evidence, and limitations
    • An aggregate accuracy score without use conditions or limitations
    • Source code without evidence or intended-use information
    • An internal report unavailable to health workers and affected users
  8. Kdo nese odpovědnost za etickou AI ve zdraví?
    • Health ministries and vendors, excluding clinicians and communities
    • Developers and regulators, excluding care providers and patients
    • Developers, providers, governments, and affected people
    • Patients and vendors alone, without health systems or public agencies